A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17p Deletion
Phase of Trial: Phase II
Latest Information Update: 03 Sep 2018
At a glance
- Drugs Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors AbbVie
- 29 May 2018 Planned primary completion date changed from 18 Jun 2021 to 29 Aug 2021.
- 28 Feb 2018 Planned End Date changed from 28 Aug 2024 to 25 Aug 2024.
- 07 Nov 2017 Status changed from not yet recruiting to recruiting.